Business
Announcement on Voluntary Disclosure of the Completion of Enrollment of the First Subject in the Phase II Clinical Trial of Hemoporfin for Injection for the Treatment of Nevus Flammeus in the United States
Announcement on Voluntary Disclosure of the Completion of Enrollment of the First Subject in the Phase II Clinical Trial of Hemoporfin for Injection for the Treatment of Nevus Flammeus in the United States
About this update from Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A
Announcement on Voluntary Disclosure of the Completion of Enrollment of the First Subject in the Phase II Clinical Trial of Hemoporfin for Injection for the Treatment of Nevus Flammeus in the United StatesThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment